Company news
Oncodesign Precision Medicine S.a. (EURONEXT:ALOPM) news
Oncodesign Precision Medicine S.a. news releases on 6ix. Latest, Apr 30, 2026: OPM Announces Its 2025 Annual Results and Provides an Update on Its Clinical…
Press releases & updates
OPM Announces Its 2025 Annual Results and Provides an Update on Its Clinical Developments
April 30, 2026
Oncodesign Precision Medicine Receives Support from The Michael J. Fox Foundation to Advance Development of LRRK2 Inhibitor OPM-201 for Parkinson’s Disease
March 3, 2026
Oncodesign Precision Medicine and Ksilink Join Forces to Test the Nanocyclix® Chemical Library in Cell Models Derived From Patients With Serious Central Nervous System Diseases
January 8, 2026
Oncodesign Precision Medicine and Navigo Proteins Announce the End of Their Collaboration in the Development of Radiotheranostics
December 29, 2025
OPM Obtains Development Grants From the Bourgogne Franche-Comté Region
October 14, 2025
OPM Publishes Its 2025 Half-Yearly Report
October 9, 2025
OPM Integrated Into the LRRK2 Investigative Therapeutics Exchange Program From the Michael J. Fox Foundation for Parkinson’s Research
September 25, 2025
OPM Announces Its 2025 Half-Year Financial Results and Provides an Update on Its Clinical Developments and Financial Position
July 31, 2025
Oncodesign Precision Medicine : Announces Equity Financing of up to 5 Million Euros
April 17, 2025
Oncodesign Precision Medicine : OPM announces equity financing of up to 5 million euros
April 17, 2025
OPM Announces Its 2024 Annual Results and Clinical Developments
April 3, 2025
Oncodesign Precision Medicine : OPM) Announces Protocol Submission for its Phase 1b/2a Study, REVERT for OPM 101 in Combination with Pembrolizumab in Patients with Advanced Melanoma Resistant to Anti PD1
March 24, 2025
Oncodesign Precision Medicine (OPM) Announces Protocol Submission for its Phase 1b/2a Study, REVERT for OPM-101 in Combination with Pembrolizumab in Patients with Advanced Melanoma Resistant to Anti-PD1
March 24, 2025
Oncodesign Precision Medicine Reacquires Rights to Its OPM-201 Program From Servier After a Positive Phase I Trial in Healthy Volunteers
December 20, 2024
OPM Reports Final Results of Its Phase 1 Study With RIPK2 Inhibitor OPM-101, With Strong Safety Data and No Cardiac Toxicity, Paving the Way for the Launch of Phase 1b/2a
October 22, 2024
OPM Announces Poster Presentation on OPM-101, a RIPK2 Kinase Inhibitor, in Healthy Volunteers at UEG Week 2024 Conference
October 15, 2024
OPM Announces Its First-half 2024 Results and Provides an Update on Its Clinical Developments, and Its Financial Situation
September 25, 2024
OPM Announces Positive Results of Its Phase 1 in Healthy Volunteers with OPM-101: Strong Target Engagement With Excellent Safety Profile
July 16, 2024
Oncodesign Precision Medicine (OPM) obtains €5.6 million in public funding for its DEMOCRITE program dedicated to the clinical development of OPM-101
April 17, 2024